Infinium Global Research has added a new report on Paroxysmal Nocturnal Hemoglobinuria Treatment Market. The report covers the analysis of global as well as regional markets of paroxysmal nocturnal hemoglobinuria treatment. Moreover, the report gives insights into the factors that affect the global as well as regional performance of the market in the short run and in the long run. According to the report, the global paroxysmal nocturnal hemoglobinuria treatment market is projected to grow at a CAGR of 11.6% over the forecast period of 2019-2025.
Ask for Sample Copy of Research Report with Table of Content @ https://www.infiniumglobalresearch.com/reports/sample-request/6063
Paroxysmal nocturnal hemoglobinuria is a rare acquired, life-threatening disease of the blood. The disease is characterized by the destruction of red blood cells (hemolytic anemia), blood clots (thrombosis), and impaired bone marrow function (State where blood components do not form in adequate proportion). PNH affects 0.5-1.5 persons per million of the population and is mainly a disease of younger adults. PNH occurs when mutations of a gene called PIG-A occur in a bone marrow stem cell. The function of Stem cells includes the production of mature blood elements like red blood cells, white blood cells, and platelets. Thus the mutated stem cells pass the PIG-A mutation to all cells derived from an abnormal stem cell. Cells carrying PIG-A mutations are deficient with GPI-anchored proteins, which play an important role in the protection of RBCs from destruction, blood clotting and involved in fighting against infection. The survival rate in younger adults after diagnosis is 10 years, however, some patients can survive for decades with only minor symptoms.
The high growth of paroxysmal nocturnal hemoglobinuria treatment market will attribute by factors such as the rising number of blood and bone marrow related disorders. National Organization for Rare Diseases (NORD) report states around 0.5-1.5 per million general population suffer from PNH. Other factors will contribute to the market growth is development in stem cell research, advancement in stem cell transplantation therapies and heavy investments for novel drug discovery (NDD). APL-2, a Complement C3 Inhibitor by Apellis pharmaceuticals is under clinical trial phase 3 for the potential treatment of paroxysmal nocturnal hemoglobinuria. However high costs associated with medical treatment and adverse side effects with existing treatments can hamper the growth of the market. On the other hand, unmet demand for drugs in developing countries can provide better growth opportunities to paroxysmal nocturnal hemoglobinuria treatment market.
U.S Will Hold the Highest Share of the Market in the Near Future
Based on geography North America, specifically, the US will hold the highest share of the market in the near future, factors such as approval for novel drugs in the pipeline, adoption of novel therapeutics will support the growth of the region in the forecast period. The market in Europe is anticipated to grow with a healthy rate in the near future, pharma major collaboration with research institutes for new drug development and high expenditure on the healthcare sector will contribute to the growth of the market. The Asia-Pacific region is expected to be on the second spot in the paroxysmal nocturnal hemoglobinuria treatment market in the forecast period. An increase in healthcare expenditure, the presence of key pharma players, and rising healthcare awareness is contributing to the growth of this region.
Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Segmentation
The report on global paroxysmal nocturnal hemoglobinuria treatment market covers segments such as diagnostic test and treatment. On the basis of diagnostic test, the sub-markets include complete blood count test (CBC), lactate dehydrogenase test (LDH), bone marrow examination, urine test for hemosiderin, flow cytometry, and other tests. On the basis of treatment, the sub-markets include medication, stem cell transplant, and blood transfusion.
Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Competitive Landscape
The report provides profiles of the companies in the market such as F. Hoffmann-La Roche AG, Akari Therapeutics, Alexion Pharmaceuticals, lnc., Ra Pharmaceuticals, Novartis AG, Alnylam Pharmaceuticals, Inc., Apellis Pharmaceuticals, Achillion Pharmaceuticals, Regeneron Pharmaceuticals, Inc., and Other Companies.
Browse Detailed TOC, Description, and Companies Mentioned in Report @ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-paroxysmal-nocturnal-hemoglobinuria-treatment-market
Reasons to Buy this Report:
- Comprehensive analysis of global as well as regional markets of the paroxysmal nocturnal hemoglobinuria treatment.
- Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2025.
- Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
- Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.